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ABSTRACT
It has long been known that radiation destroys the tumors 
by killing cells. However, immunotherapy is developing 
rapidly, combination of immunotherapy with chemotherapy 
and radiotherapy seems to be a viable option. Preclinical 
studies combining immunotherapy with radiotherapy 
resulted in promising data, where manipulating immune 
response enhances the effects of radiation. There are many 
ways of immunotherapy-radiotherapy combination, and the 
field is open for clinical research. This paper reviews the 
current situation on this topic. 
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Introduction
Radiotherapy is an important component of the classical 
anticancer treatment. The effects of radiation on the 
irradiated organs and tissues are well known since mid-
20th century, which shaped the radiotherapy until recent 
decade. Radiation response at the cellular level and radiation 
interactions with subcellular structures and molecules are 
the current focus of the radiation research which expected to 
contribute to the science of radiation oncology in the coming 
decades [1]. 
Radiation attacks DNA and mediates its effects by 
killing of cells. We know that cancer cells are more prone 
to death from unrepaired DNA damage than the normal 
cells; radiation oncologists to treat the cancer patients 
without creating serious side effects use this gap. Broken 
and unrepaired DNA either kills the cell through necrosis or 
apoptosis, where the final result is the disintegration of the 
cell and phagocytosis of the cellular elements. Frequently 
the cell survives DNA damage but loses its replicating 
capacity and sometimes many of its functions discontinue 
where the cell is forced to live in a steady state, which is 
called senescence [2]. 
In addition to its tumoricidal effects there is strong evidence 
that radiation also activates the immune system and enhances 
immune responses. At first sight radiation directed activation 
of the immune system seems to be contradictory, since 
radiotherapy – like chemotherapy – has long been considered 
as immunosuppressive [1, 2]. However, recent studies showed 
that cytotoxic treatments have immunostimulatory effects on 
tumor cells and their microenvironment. Although currently 
we know only a tiny part of the all mechanisms and molecules 
involved in immunostimulation process, it is worthwhile to 
research this field [3]. 
There is a promising experimental data supporting the 
combination of radiotherapy with various immunotherapy 
techniques, however further clinical studies are required 
to translate this data into daily practice. Combining 
radiotherapy with immunotherapy may open new frontiers 
in the cancer treatment [4].
In this paper, we summarize, the existing knowledge on 
radiation and immune response and review preclinical and 
clinical data on the use of radiotherapy with immunotherapy.
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Tumor immunology 
Identification and elimination of tumors is among the 
important roles of the immune system. Tumors include 
transformed cells expressing antigens, which are not found on 
normal cells of an individual. These antigens are considered 
to be alien by the immune system, which provokes the attack 
of immune cells to those antigen bearing tumor cells [1].
The antigens expressed by tumors originate from several 
sources. These may be acquired from oncogenic viruses 
like human papillomavirus, a common cause of cervix uteri 
cancers, while others are the individual’s own proteins that 
express at low levels in normal cells but reach high levels in 
tumor cells. Another source of tumor antigens are oncogenes 
- proteins playing role in regulating cell growth and survival 
that commonly mutate into cancer inducing molecules [5]. 
Once a tumor antigen is identified, the immune system 
destroys the abnormal cells using killer T cells, sometimes 
with the assistance of helper T cells. Tumor antigens are 
presented in a similar way to viral antigens, which allows 
killer T cells to recognize the tumor cell as abnormal. 
Natural killer (NK) cells also kill tumor cells in a similar 
way, especially when the tumor cells have fewer MHC class 
I molecules on their surface than normal, which is common 
with tumors. Sometimes antibodies are generated against 
tumor cells as well allowing for their destruction by the 
complement system [1-3].
Unfortunately, tumors may overcome the suppression 
by the immune system and proceed to become cancers, 
this process is called immune evasion. Many tumor cells 
have a reduced number of MHC class I molecules on their 
surface, and avoid detection by killer T cells. Some tumor 
cells able to suppress the activity of macrophages and 
lymphocytes through releasing molecules that inhibit the 
immune response, such as secreting the cytokine TGF-β. 
Finally, immunological tolerance against tumor antigens 
may develop which results in the silencing of the immune 
system against the tumor cells [6]. 
Interaction between radiation and immune system
Ionizing radiation causes immunogenic death of cancer 
cells, modulates antigen presentation by cancer cells, and 
most importantly alters the microenvironment within the 
irradiated field. Cells composing the immune system are 
usually rapidly dividing and proliferating, thus most of 
them are extremely radiosensitive. Within the irradiated 
field almost all immune system cells are depleted including 
cytotoxic T Lymphocytes (CTLs) and NK cells that are 
directed against the tumor, and regulatory T lymphocytes 
(Tregs) programmed to suppress local anti-tumor immunity. 
The relative importance of these alterations caused by 
radiation is still not clear, but we know that immune system 
senses this damage and triggers immune response pathways 
resulting in several systemic implications [1]. 
Once a cell is destroyed by radiation, a number of tumor 
antigens are released to extracellular matrix. These antigens 
contact with T lymphocytes and causes differentiation of 
these lymphocytes to antitumor CTLs through a process 
called immune priming [7]. Several molecules including 
HMGB1, uric acid and heat shock proteins (HSPs) are 
among those released from the cellular fragments, where 
HSPs serve as a marker of damaged cells for elimination by 
the immune system and facilitate antigen cross-presentation, 
dendritic cell (DC) maturation, and NK cell activation 
[8]. Overall result of these processes is the induction and 
amplification of antitumor responses. The most important 
event is the uptake of tumor antigens by macrophages 
and DCs. This process is mediated by the translocation of 
calreticulin from the endoplasmic reticulum of tumor cells 
to the cell surface. Radiation damage causes calreticulin 
to translocate to the tumor cell surface where it sends a 
message to macrophages and DCs for identifying the tumor 
as an enemy, and directs macrophages and DCs to absorb 
calreticulin expressing tumor cells [9].
Fig 1: Schematic drawing of the immunologic events after the 
tumor cell is destructed by radiation. Antigens released from the 
tumor cells are considered as foreign by T-lymphocytes and an 
immune process is started. CTLs directed to tumor attacks not only 
to tumor bulk in the irradiated area but also to all antigen bearing 
tumor cells within the organism, a process called abscopal effect.
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Tumor eradication through immunologic cell death 
has also been linked with radiation-induced DNA damage 
pathways via ataxia telangiectasia mutated (ATM) protein 
and p53. In the presence of ATM, DNA-damaged tumor 
cells can up regulate ligands such as NKG2D, making 
those more efficiently recognized for elimination by NK 
and activated CD8+ T cells [10].
 
Systemic antitumor immune response (Abscopal 
effect) 
Radiotherapy directed to a tumor locally may induce 
regression of metastatic cancers at distant sites, which 
are away from the irradiation field. This phenomenon 
is called abscopal effect. Although it is extremely rare, 
its effect on the cancer can be stunning, leading to the 
disappearance of malign deposits throughout the entire 
body. Several cases were reported for a variety of cancers, 
including melanomas, cutaneous lymphomas, and renal 
cancers. Abscopal effect appears to be a result of enhanced 
immune response directed to tumor cells. While there is 
evidence that radiotherapy can induce cross-priming of 
CTLs against tumor antigens, this subsequent effect of 
local irradiation appears to be relatively insignificant. 
Although radiotherapy presents new antitumor CTLs, 
these usually cannot overcome the suppressive effect of 
the tumor microenvironment at distant metastatic sites; 
this explains why abscopal responses are not seen in daily 
routine practice. 
The destructive effects of the radiation on the immune 
system cells, along with the unsuccessful results of the 
early immunotherapies prevented the idea of combining 
radiotherapy with immunotherapy. However, today’s 
genetic engineering techniques allow us to manipulate 
DNA and enable to enhance systemic immune response 
of radiotherapy, which sets the rationale for combining 
systemic immunotherapies with radiotherapy. Used 
together, radiotherapy and immunotherapy may have 
synergistic effects and may shift the tumor immune system 
balance toward elimination of all systemic tumor cells. 
Even the “infield” effects of radiation have been shown to 
be dependent on the immune system, as CD8+T cells and 
Type-1 interferon are required for tumor regression after 
radiotherapy, since their depletion impairs tumor control 
after irradiation [11-13].
Clinical trials involving radiation and 
immunotherapy
Promising preclinical data from combined approach of RT 
and immunotherapy has led to clinical trials and a number 
of phase I-II clinical studies translated the experimental 
research into clinical setting successfully. 
Ipilimumab is the first antibody to modulate tumor 
immunology approved by FDA for clinical use. This 
molecule binds to CTLA-4 (cytotoxic T lymphocyte-
associated antigen 4) which is a protein receptor that down 
regulates the immune system through inhibitory signals 
on CTLs. Ipilimumab silences the inhibitory signal of 
CTLA-4 on CTLs and allow them to recognize and destroy 
cancer cells [3]. Apart from preclinical data there is also a 
case report describing disappearance of malign melanoma 
deposits in a patient who was under ipilimumab treatment 
and received paraspinal irradiation to palliate a mestastatic 
mass. This phenomenon was attributed to abscopal effect, 
and increases the enthusiasm for studying ipilimumab and 
radiotherapy combination. Ongoing phases I - II trials on 
malign melanoma are testing the use of ipilimumab with 
radiotherapy. 
Dendritic cell vaccines are also in the focus of 
radiation researchers. So far radiotherapy and vaccine 
combinations demonstrated less activity probably 
related to immunosuppressive effects of the tumor 
microenvironment. Future combinations of cancer vaccines 
with immunotherapeutics that enhance T-cell function 
or modulate the tumor microenvironment may be more 
effective [6]. 
The safety of combining radiotherapy with 
immunotherapy has always been a question. A phase-I 
demonstrated the safety of combining stereotactic body 
RT and interleukin-2, an FDA-approved immunotherapy 
for metastatic renal cell carcinoma and melanoma. 
Response rates were better in this study when compared to 
historical data. A similar single- arm phase I-II study also 
demonstrated safety and feasibility of combining local RT 
with a TLR9 agonist [14].
One of the most popular questions yet to be answered 
is the use of immunotherapeutics to modify the 
immune-suppressive tumor microenvironment prior to 
radiotherapy. Radiation has its own local effects on the 
tumor microenvironment, and modulation of the tumor 
microenvironment has the potential to boost the systemic 
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anti-tumor-immune response. However currently we have 
very few data for the dose and fractionation, irradiation 
site, timing and sequencing of combined modalities. This 
area requires further research.
Dose and fractionation are important factors in the 
immunogenicity of RT. Pre-clinical data demonstrated that, 
8 Gy in three fractions or 6 Gy in five fractions are superior 
to standard fractionation or a single dose of 20 Gy when 
combined with ipilimumab [15]. This is probably related 
with the difference in immune effect between different 
dose and fractionation schedules, but these schedules 
are supported by clinical reports of abscopal effect after 
palliative radiotherapy to a single metastatic site in malignant 
melanoma (9.5 Gy x 3) and non-small cell lung cancer (6 Gy 
x 5) [16, 17]. 
The target site of radiotherapy may be another 
important consideration when combining radiation with 
immunotherapy. Preclinical models are not cleared yet the 
best way to maximize abscopal effect. Is there a correlation 
between the amount of the irradiated tumor and the size of 
the abscopal effect? If so, should we irradiate some of the 
metastatic deposits besides primary tumor? Or is it good 
enough to irradiate only a portion of the primary to trigger 
abscopal phenomenon? At the moment, the only data we 
can get from the clinical reports of abscopal effect is that 
this phenomenon is observed after radiotherapy targeting 
visceral metastases [18-21]. 
The timing of radiotherapy - immunotherapy 
combination is another important question needs to be 
answered. One possible order may be the manipulation of 
the immune system by immunotherapy and preparation 
for irradiation afterwards, but we have no idea yet for the 
optimum gap between these two modalities. Of course other 
combination scenarios considering not only radiotherapy 
and immunotherapy but also chemotherapy and even surgery 
should be considered as well.
Conclusions
Immunotherapy is developing rapidly. There are numerous 
preclinical studies involving immunotherapy, where some 
of them combining with radiation  (Table 1). Manipulation 
of the immune response may enhance the effects of 
radiation both locally or systemically through abscopal 
effect. Promising preclinical data on this combination is 
already accumulated and clinical studies are just starting. 
Immunotherapy combination may shape the future of 
radiotherapy.
Table I: Current ongoing trials testing combination of radiotherapy and immunotherapy https://clinicaltrials.gov
Study Tumor Site Primary endpoint Radiotherapy schedule
NCT01703507 Metastatic melanoma to brain
-Determine the maximum tolerated dose 
(MTD) of ipilimumab when combined 
with whole-brain radiation therapy 
(WBRT) or stereotactic radiosurgery 
(SRS)
SRS doses: 24, 21, 18, and 15 Gy. 
Whole-brain radiation dose: 37.5 Gy
NCT01416831 
Phase -II randomized Metastatic melanoma
-Compare response rate of high dose 
IL- 2.
-Measure the response of SBRT and IL 
-2 in crossover patients with melanoma 
who have disease progression after high 
dose IL- 2 alone. 
20 Gy x 1 and 20 Gy x 2
NCT01903083 / phase-I
Locally advanced and 
borderline resectable pancreatic 
cancer 
-Evaluate the safety of combination 
gemcitabine, tadalafil, and
hypofractionated radiation
8-10 Gy x 3
NIH/NCI11-C- 0247
NCT01496 
Phase –I
High- or intermediate risk 
prostate cancer
-Evaluate the effect of the MUC1-
specific vaccine (stimuvax/L-BLP25/
tecemotide) on systemic immune
responses when given in combination 
with standard radiation and
androgen-deprivation therapy
Conventional dose and fractionation
NIH/NCI # pending Metastatic colorectal cancer
-Evaluate the safety of AMP-224—a 
PD-1 inhibitor—in combination with 
SBRT in patients with metastatic col-
orectal cancer.
8 Gy x 1 or 8 Gy x 3
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